Avidity Biosciences (RNA)
(Delayed Data from NSDQ)
$38.26 USD
+0.92 (2.46%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $38.50 +0.24 (0.63%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RNA 38.26 +0.92(2.46%)
Will RNA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RNA
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates
Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates
RNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
Other News for RNA
Avidity Biosciences (RNA) Completes Enrollment for Phase 3 DM1 Treatment Trial
Avidity Biosciences completes enrollment in Phase 3 HARBOR clinical trial
Avidity gets FDA breakthrough therapy status for DMD treatment
Avidity Biosciences (RNA) Secures Breakthrough Therapy Designation from FDA | RNA Stock News